Alternative delivery of a thermostable inactivated polio vaccine

被引:19
作者
Kraan, Heleen [1 ]
Ploemen, Ivo [1 ]
van de Wijdeven, Gijsbert [2 ]
Que, Ivo [3 ]
Loewik, Clemens [3 ]
Kersten, Gideon [1 ,4 ]
Amorij, Jean-Pierre [1 ]
机构
[1] Intravacc Inst Translat Vaccinol, Bilthoven, Netherlands
[2] Bioneedle Technol Grp BV, Eindhoven, Netherlands
[3] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands
[4] Leiden Univ, Leiden Acad Ctr Drug Res, Div Drug Delivery Technol, Leiden, Netherlands
关键词
Bioneedles; Vaccine delivery; Biodistribution; Needle free; Adjuvant; D-ANTIGEN; ADJUVANT; IMMUNOGENICITY;
D O I
10.1016/j.vaccine.2015.03.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the near future oral polio vaccine (OPV) will be replaced by inactivated polio vaccine (IPV) as part of the eradication program of polio. For that reason, there is a need for substantial amount of safe and more affordable IPV for low-income countries. Bioneedles, which are biodegradable mini-implants, have the potential to deliver vaccines outside the cold-chain and administer them without the use of needles and syringes. In the current study, Bioneedles were filled with IPV, subsequently lyophilized, and antigenic recoveries were determined both directly after IPV-Bioneedle preparation as well as after elevated stability testing. Further, we assessed the immunogenicity of IPV-Bioneedles in rats and the residence time at the site of administration. Trivalent IPV was formulated in Bioneedles with recoveries of 101 10%, 113 18%, and 92 15%, respectively for serotypes 1, 2 and 3. IPV in Bioneedles is more resistant to elevated temperatures than liquid IPV: liquid IPV retained less than half of its antigenicity after 1 day at 45 degrees C and IPV in Bioneedles showed remaining recoveries of 80 10%, 85 4% and 63 4% for the three serotypes. In vivo imaging revealed that IPV administered via Bioneedles as well as subcutaneously injected liquid IPV showed a retention time of 3 days at the site of administration. Finally, an immunogenicity study showed that IPV-filled Bioneedles are able to induce virus-neutralizing antibody titers similar to those obtained by liquid intramuscular injection when administered in a booster regime. The addition of LPS-derivate PagL in IPV-filled Bioneedles did not increase immunogenicity compared to IPV-Bioneedles without adjuvant. The current study demonstrates the pre-clinical proof of concept of IPV-filled Bioneedles as a syringe-free alternative delivery system. Further pre-clinical and clinical studies will be required to assess the feasibility whether IPV-Bioneedles show sufficient safety and efficacy, and may contribute to the efforts to eradicate and prevent polio in the future. (C) 2015 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:2030 / 2037
页数:8
相关论文
共 50 条
[32]   Immune Response of Gamma-Irradiated Inactivated Bivalent Polio Vaccine Prepared plus Trehalose as a Protein Stabilizer in a Mouse Model [J].
Mollaei Alamuti, Maryam ;
Ravanshad, Mehrdad ;
Motamedi-Sedeh, Farahnaz ;
Nabizadeh, Arezoo ;
Ahmadi, Elham ;
Hossieni, Seyedeh Maedeh .
INTERVIROLOGY, 2021, 64 (03) :140-146
[33]   A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery [J].
Gerhardt, Alana ;
Voigt, Emily ;
Archer, Michelle ;
Reed, Sierra ;
Larson, Elise ;
Van Hoeven, Neal ;
Kramer, Ryan ;
Fox, Christopher ;
Casper, Corey .
MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2022, 25 :205-214
[34]   Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine [J].
Xu, Jiawei ;
Liu, Yang ;
Qiu, Wei ;
Li, Wenwen ;
Hu, Xiaoxiao ;
Li, Xia ;
Fan, Qiang ;
Tang, Wenge ;
Wang, Yujie ;
Wang, Qing ;
Yao, Ning .
BMC INFECTIOUS DISEASES, 2024, 24 (01)
[35]   Parental acceptance of inactivated polio vaccine in Southeast Nigeria: A qualitative cross-sectional interventional study [J].
Tagbo, Beckie Nnenna ;
Ughasoro, Maduka Donatus ;
Esangbedo, Dorothy Omono .
VACCINE, 2014, 32 (46) :6157-6162
[36]   Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization [J].
Okayasu, Hiromasa ;
Sein, Carolyn ;
Blanc, Diana Chang ;
Gonzalez, Alejandro Ramirez ;
Zehrung, Darin ;
Jarrahian, Courtney ;
Macklin, Grace ;
Sutter, Roland W. .
JOURNAL OF INFECTIOUS DISEASES, 2017, 216 :S161-S167
[37]   Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine [J].
Brickley, Elizabeth B. ;
Strauch, Carolyn B. ;
Wieland-Alter, Wendy F. ;
Connor, Ruth I. ;
Lin, Shu ;
Weiner, Joshua A. ;
Ackerman, Margaret E. ;
Arita, Minetaro ;
Oberste, M. Steven ;
Weldon, William C. ;
Saez-Llorens, Xavier ;
Bandyopadhyay, Ananda S. ;
Wright, Peter F. .
JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (03) :371-380
[38]   Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine [J].
Knutsson, N ;
Trollfors, B ;
Taranger, J ;
Bergfors, E ;
Sundh, V ;
Lagergård, T ;
Östergaard, E ;
Cicirello, H ;
Käyhty, H .
VACCINE, 2001, 19 (31) :4396-4403
[39]   A mucosal adjuvant for the inactivated poliovirus vaccine [J].
Steil, Benjamin P. ;
Jorquera, Patricia ;
Westdijk, Janny ;
Bakker, Wilfried A. M. ;
Johnston, Robert E. ;
Barro, Mario .
VACCINE, 2014, 32 (05) :558-563
[40]   Buccal and sublingual vaccine delivery [J].
Kraan, Heleen ;
Vrieling, Hilde ;
Czerkinsky, Cecil ;
Jiskoot, Wim ;
Kersten, Gideon ;
Amorij, Jean-Pierre .
JOURNAL OF CONTROLLED RELEASE, 2014, 190 :580-592